A strategic model for developing vaccines against neglected diseases: An example of industry collaboration for sustainable development

References

• United Nations General Assembly. Transforming our world: the 2030 agenda for sustainable development; 2015 [accessed 2021 Jul 29. http://www.un.org/ga/search/view_doc.asp?symbol=A/RES/70/1&Lang=E.
   Google Scholar
• Levels & trends in child mortality. Report 2019. Estimates developed by the UN Inter-agency Group for Child Mortality Estimation; 2019 [accessed 2021 Jul 26]. http://childmortality.org/wp-content/uploads/2019/10/UN-IGME-Child-Mortality-Report-2019.pdf.
   Google Scholar
• Liu L, Oza S, Hogan D, Chu Y, Perin J, Zhu J, Lawn JE, Cousens S, Mathers C, Black RE. Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the sustainable development goals. Lancet. 2016;388(10063):1–9. doi:10.1016/s0140-6736(16)31593-8.
   PubMed Web of Science ®Google Scholar
• Chapman N, Doubell A, Barnsley P, Goldstein M, Oversteegen L, Chowdhary V, Rugarabamu G, Ong M, Borri J, Hynen A, Policy Cures Research, et al. G-Finder 2019. Uneven progress 2019. http://s3-ap-southeast-2.amazonaws.com/policy-cures-website-assets/app/uploads/2020/02/11150341/G-Finder2019.pdf.
   Google Scholar
• Chapman N, Doubell A, Tuttle A, Barnsley P, Goldstein M, Oversteegen L, Chowdhary V, Borri J, Hynen A, Kearney M. Policy Cures Research. G-Finder 2020. Neglected disease research and development: Where to now? 2020. http://policy-cures-website-assets.s3.ap-southeast-2.amazonaws.com/wp-content/uploads/2021/04/15055816/G-FINDER-2020_Final-Report.pdf.
   Google Scholar
• Podda A. Aims and role of Novartis Vaccines Institute for Global Health (NVGH). Procedia Vaccinol. 2010;2(2):124–27. doi:10.1016/j.provac.2010.07.003.
   Google Scholar
• Saul A, Rappuoli R. The Novartis Vaccines Institute for Global Health: a new initiative for developing vaccines for neglected diseases in developing countries. J Infect Dev Ctries. 2009;2(2):154–55. doi:10.3855/t2.2.154.
   PubMed Web of Science ®Google Scholar
• Saul A, O’Brien KL. Prioritizing vaccines for developing world diseases. Vaccine. 2017;35(Suppl 1):A16–19. doi:10.1016/j.vaccine.2016.10.087.
   PubMedGoogle Scholar
• GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–858. doi:10.1016/s0140-6736(18)32279-7.
   PubMed Web of Science ®Google Scholar
• Troeger C, Colombara DV, Rao PC, Khalil IA, Brown A, Brewer TG, Guerrant RL, Houpt ER, Kotloff KL, Misra K, et al. Global disability-adjusted life-year estimates of long-term health burden and undernutrition attributable to diarrhoeal diseases in children younger than 5 years. Lancet Glob Health. 2018;6(3):e255–e269. doi:10.1016/s2214-109x(18)30045-7.
   PubMed Web of Science ®Google Scholar
• GBD 2017 Typhoid and Paratyphoid Collaborators. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Infect Dis. 2019;19(4):369–81. doi:10.1016/s1473-3099(18)30685-6.
   PubMed Web of Science ®Google Scholar
• Basnyat B, Qamar FN, Rupali P, Ahmed T, Parry CM. Enteric fever. BMJ. 2021;372:n437. doi:10.1136/bmj.n437.
   PubMedGoogle Scholar
• Prudden HJ, Hasso-Agopsowicz M, Black RE, Troeger C, Reiner RC, Breiman RF, Jit M, Kang G, Lamberti L, Lanata CF, et al. Meeting Report: WHO workshop on modelling global mortality and aetiology estimates of enteric pathogens in children under five. Cape Town, 28-29th November 2018. Vaccine. 2020;38(31):4792–800. doi:10.1016/j.vaccine.2020.01.054.
   PubMed Web of Science ®Google Scholar
• Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–27. doi:10.1016/s1473-3099(17)30753-3.
   PubMed Web of Science ®Google Scholar
• Appiah GD, Chung A, Bentsi-Enchill AD, Kim S, Crump JA, Mogasale V, Pellegrino R, Slayton RB, Mintz ED. Typhoid outbreaks, 1989-2018: implications for prevention and control. Am J Trop Med Hyg. 2020;102(6):1296–305. doi:10.4269/ajtmh.19-0624.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Typhoid vaccines: WHO position paper. Week Epidemiol Rec. 2008;83(6):49–59.
   PubMedGoogle Scholar
• John J, Van Aart CJ, Grassly NC. The burden of typhoid and paratyphoid in India: systematic review and meta-analysis. PLoS Negl Trop Dis. 2016;10(4):e0004616. doi:10.1371/journal.pntd.0004616.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay B, Sur D, Gupta SS, Ganguly NK. Typhoid fever: control & challenges in India. Indian J Med Res. 2019;150(5):437–47. doi:10.4103/ijmr.IJMR_411_18.
   PubMed Web of Science ®Google Scholar
• Browne AJ, Kashef Hamadani BH, Kumaran EAP, Rao P, Longbottom J, Harriss E, Moore CE, Dunachie S, Basnyat B, Baker S, et al. Drug-resistant enteric fever worldwide, 1990 to 2018: a systematic review and meta-analysis. BMC Med. 2020;18(1):1. doi:10.1186/s12916-019-1443-1.
   PubMed Web of Science ®Google Scholar
• Yousafzai MT, Karim S, Qureshi S, Kazi M, Memon H, Junejo A, Khawaja Z, Ur Rehman N, Ansari MS, Ali R, et al. Effectiveness of typhoid conjugate vaccine against culture-confirmed Salmonella enterica serotype Typhi in an extensively drug-resistant outbreak setting of Hyderabad, Pakistan: a cohort study. Lancet Glob Health. 2021;9(8):e1154–e1162. doi:10.1016/s2214-109x(21)00255-2.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Typhoid vaccines: WHO position paper, March 2018 - recommendations. Vaccine. 2019;37(2):214–16. doi:10.1016/j.vaccine.2018.04.022.
   PubMed Web of Science ®Google Scholar
• Pulickal AS, Pollard AJ. Vi polysaccharide-protein conjugate vaccine for the prevention of typhoid fever in children: hope or hype? Expert Rev Vaccines. 2007;6(3):293–95. doi:10.1586/14760584.6.3.293.
   PubMed Web of Science ®Google Scholar
• Szu SC, Stone AL, Robbins JD, Schneerson R, Robbins JB. Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals. J Exp Med. 1987;166(5):1510–24. doi:10.1084/jem.166.5.1510.
   PubMed Web of Science ®Google Scholar
• Lin FY, Ho VA, Khiem HB, Trach DD, Bay PV, Thanh TC, Kossaczka Z, Bryla DA, Shiloach J, Robbins JB, et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med. 2001;344(17):1263–69. doi:10.1056/nejm200104263441701.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO prequalified vaccines. [accessed 2021 Oct 29]. http://extranet.who.int/pqweb/vaccines/prequalified-vaccines.
   Google Scholar
• Akram J, Khan AS, Khan HA, Gilani SA, Akram SJ, Ahmad FJ, Mehboob R. Extensively Drug-Resistant (XDR) typhoid: evolution, prevention, and its management. Biomed Res Int. 2020;2020:6432580. doi:10.1155/2020/6432580.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. HAN archive - 00439: extensively drug-resistant Salmonella Typhi infections among U.S. residents without international travel; 2021 Feb 12 [accessed 2021 Aug 24]. http://emergency.cdc.gov/han/2021/han00439.asp.
   Google Scholar
• Szu SC, Klugman KP, Hunt S. Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young children. Vaccine. 2014;32(20):2359–63. doi:10.1016/j.vaccine.2014.02.050.
   PubMed Web of Science ®Google Scholar
• Rondini S, Micoli F, Lanzilao L, Hale C, Saul AJ, Martin LB. Evaluation of the immunogenicity and biological activity of the Citrobacter freundii Vi-CRM197 conjugate as a vaccine for Salmonella enterica serovar Typhi. Clin Vaccine Immunol. 2011;18(3):460–68. doi:10.1128/cvi.00387-10.
   PubMedGoogle Scholar
• Rondini S, Micoli F, Lanzilao L, Pisoni I, Di Cioccio V, Saul AJ, Martin LB. Characterization of Citrobacter sp. line 328 as a source of Vi for a Vi-CRM197 glycoconjugate vaccine against Salmonella Typhi. J Infect Dev Ctries. 2012;6(11):763–73. doi:10.3855/jidc.2495.
   PubMed Web of Science ®Google Scholar
• Micoli F, Adamo R, Costantino P. Protein carriers for glycoconjugate vaccines: history, selection criteria, characterization and new trends. Molecules. 2018;23(6):1451. doi:10.3390/molecules23061451.
   PubMed Web of Science ®Google Scholar
• Pichichero ME. Protein carriers of conjugate vaccines: characteristics, development, and clinical trials. Hum Vaccin Immunother. 2013;9(12):2505–23. doi:10.4161/hv.26109.
   PubMed Web of Science ®Google Scholar
• Micoli F, Rondini S, Pisoni I, Proietti D, Berti F, Costantino P, Rappuoli R, Szu S, Saul A, Martin LB. Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi. Vaccine. 2011;29(4):712–20. doi:10.1016/j.vaccine.2010.11.022.
   PubMed Web of Science ®Google Scholar
• van Damme P, Kafeja F, Anemona A, Basile V, Hilbert AK, De Coster I, Rondini S, Micoli F, Qasim Khan RM, Marchetti E, et al. Safety, immunogenicity and dose ranging of a new Vi-CRM197 conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults. PLoS One. 2011;6(9):e25398. doi:10.1371/journal.pone.0025398.
   PubMed Web of Science ®Google Scholar
• Bhutta ZA, Capeding MR, Bavdekar A, Marchetti E, Ariff S, Soofi SB, Anemona A, Habib MA, Alberto E, Juvekar S, et al. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and Southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials. Lancet Infect Dis. 2014;14(2):119–29. doi:10.1016/s1473-3099(13)70241-x.
   PubMed Web of Science ®Google Scholar
• Arcuri M, Di Benedetto R, Cunningham AF, Saul A, MacLennan CA, Micoli F. The influence of conjugation variables on the design and immunogenicity of a glycoconjugate vaccine against Salmonella Typhi. PLoS One. 2017;12(12):e0189100. doi:10.1371/journal.pone.0189100.
   PubMed Web of Science ®Google Scholar
• Micoli F, Bjarnarson SP, Arcuri M, Aradottir Pind AA, Magnusdottir GJ, Necchi F, Di Benedetto R, Carducci M, Schiavo F, Giannelli C, et al. Short Vi-polysaccharide abrogates T-independent immune response and hyporesponsiveness elicited by long Vi-CRM(197) conjugate vaccine. Proc Natl Acad Sci USA. 2020;117(39):24443–49. doi:10.1073/pnas.2005857117.
   PubMed Web of Science ®Google Scholar
• Festa G, Kolte A, Carli MR, Rossi M. Envisioning the challenges of the pharmaceutical sector in the Indian health-care industry: a scenario analysis. J Bus Ind Marketing. 2022;37(8):1662–74. doi:10.1108/JBIM-07-2020-0365.
   Web of Science ®Google Scholar
• Siddalingaiah N, Tuluva S, Turaga K. A multicentre single blind randomised controlled phase-II/III study to evaluate immunogenicity and safety of single intramuscular dose of Biological E’s Vi-capsular polysaccharide-CRM197 conjugate typhoid vaccine in healthy infants, children and adults in comparison with a licensed comparator, IAP ResRCHcon 2020 Abstracts. Indian J Pediatr. 2020;87(11):974–88. doi:10.1007/s12098-020-03504-8.
   PubMedGoogle Scholar
• Kasi SG, Shivananda S, Marathe S, Chatterjee K, Agarwalla S, Dhir SK, Verma S, Shah AK, Srirampur S, Kalyani S, et al. Indian Academy of Pediatrics (IAP) Advisory Committee on Vaccines and Immunization Practices (ACVIP): recommended immunization schedule (2020-21) and update on immunization for children aged 0 through 18 years. Indian Pediatr. 2021;58(1):44–53. doi:10.1007/s13312-021-2096-7.
   PubMed Web of Science ®Google Scholar
• Coalition against typhoid, typhoid vaccine acceleration consortium. TYPHIBEV: Questions & Answers; 2021 [accessed 2021 Jul 29]. http://www.coalitionagainsttyphoid.org/wp-content/uploads/2021/06/TYPHIBEV-QA_May-2021.pdf.
   Google Scholar
• Butler D. Translational research: crossing the valley of death. Nature. 2008;453(7197):840–42. doi:10.1038/453840a.
   PubMed Web of Science ®Google Scholar
• Kaslow DC, Black S, Bloom DE, Datla M, Salisbury D, Rappuoli R. Vaccine candidates for poor nations are going to waste. Nature. 2018;564(7736):337–39. doi:10.1038/d41586-018-07758-3.
   PubMed Web of Science ®Google Scholar
• O’Brien KL, Binka F, Marsh K, Abramson JS. Mind the gap: jumping from vaccine licensure to routine use. Lancet. 2016;387(10031):1887–89. doi:10.1016/s0140-6736(16)30394-4.
   PubMed Web of Science ®Google Scholar
• Excler JL, Privor-Dumm L, Kim JH. Supply and delivery of vaccines for global health. Curr Opin Immunol. 2021;71:13–20. doi:10.1016/j.coi.2021.03.009.
   PubMed Web of Science ®Google Scholar
• Samarasekera U. CEPI prepares for future pandemics and epidemics. Lancet Infect Dis. 2021;21(5):608. doi:10.1016/s1473-3099(21)00216-4.
   PubMed Web of Science ®Google Scholar